Notably, the stomach is full after a meal, and LHQW does not directly contact the gastric mucosa, which reduces the risk of irritation of stomach mucous membrane and thus the occurrence of side-effects. Vahl. the contents by NLM or the National Institutes of Health. Lianhua Qingwen combined with conventional treatment obviously improved COVID-19. Literature Analysis of Clinical Application and Adverse Drug Reaction/Event of Lianhua Qingwen Capsule. Additionally, LHQW group also had shorter time to recovery of fever, fatigue and coughing, and higher improvement rate in chest computed tomographic manifestations and clinical cure [43]. Lu Z.J., Wu L.Y., Mou Y.Y., Duan H.M., Chen R.C., Xiao Y., Zheng W.J. Mo H.Y., Yang Z.F., Zheng J.P., Mo Z.Y., Li Y.M., Xiao Z.L. Liu Y., Liu L., Cao M.M., Wen J., Zhou S., Jiang H., Zhang Y., Zhao R.S., Yang Y.H. 52 (3), 5860. Lianhua Qingwen, the traditional Chinese medicine recently approved for use in the Philippines by the country's Food and Drugs Administration (FDA), only treats symptoms of the coronavirus disease 2019 (COVID-19), and not the disease itself, a traditional Chinese medicine physician said Tuesday. All authors approved the final version of this manuscript. Chin. doi:10.1016/s1043661802002104, Hallas, J., Harvald, B., Gram, L. F., Grodum, E., Brsen, K., Haghfelt, T., et al. There was no statistically significant difference in the incidence of adverse reactions during treatment of hand-foot-mouth disease between the LHQW group and the conventional drug group (RR = 0.53, 95% CI = 0.221.30, p = 0.165). Contraindications . However, the efficacy and safety of which shall be confirmed by more high-quality clinical trials. Similar results were obtained in subgroup analysis of hepatic function abnormal and transaminase increased. [19], Although the medicine has been allowed to be sold in Canada since 2012, Health Canada has cautioned against the use of the Chinese traditional medicine to prevent, treat, and cure COVID-19. Copyright 2022 Hu, He, Gong, Liang, Zhao and Zhang. Duan Z.P., Jia Z.H., Zhang J., Liu S., Chen Y., Liang L.C., Zhang C.Q., Zhang Z., Sun Y., Zhang S.Q., Wang Y.Y., Wu Y.L. Four studies reported body as a whole-general disorders as an adverse event. Experimental study on prevention and treatment of influenza virus FM1 infection in mice by Lianhua Qingwen capsule. Peng L.L., Li L., Shen L., Li X.L. Few reports of adverse reactions in the course of treating COVID-19 pneumonia with LHQW are available. Systematic review of efficacy and safety of Lianhua Qingwen capsules in treatment of viral influenza. (2015). The sensitivity results are shown in Table 2. Five studies reported treatment of COVID-19 pneumonia, with two documenting adverse reactions. (Nat. (2020) identified 38 randomized controlled trials (RCTs) comparing LHQW with antivirals or other Chinese medicines for treating influenza and reported a lower risk of adverse reactions in the LHQW group compared to oseltamivir (RR = 0.29, 95%CI = 0.110.80), and ribavirin groups (RR = 0.29, 95%CI = 0.110.80). In recent years, LHQW has played a significant role in the prevention and control of viral public health events (Yao et al., 2020), and is widely accepted as a representative antiviral Chinese medicine in China. 12 (12), 753759754755. 327 (7414), 557560. Control. Lianhua-qingwen Displays Antiviral and Anti-inflammatory Activity and Synergistic Effects with Oseltamivir against Influenza B Virus Infection in the Mouse Model. Protection against COVID-19 injury by qingfei paidu decoction via anti-viral, anti-inflammatory activity and metabolic programming. We would like to express our appreciation to all authors of eligible studies which were included in the current meta-analysis. Hu K., Guan W.J., Bi Y., Zhang W., Li L., Zhang B., Liu Q., Song Y., Li X., Duan Z., Zheng Q., Yang Z., Liang J., Han M., Ruan L., Wu C., Zhang Y., Jia Z.H., Zhong N.S. Modern pharmacological studies have shown that Lianhua Qingwen Prescription, as a traditional Chinese medicine prescription, has extensive antiviral and immunomodulatory effects on a series of influenza viruses. Res. Ma Y., Zhang Z., Wei L., He S., Deng X., Ji A., Zhou B., Jiang D., Li M., Wang Y. Efficacy and safety of Reduqing granules in the treatment of common cold with wind-heat syndrome: a randomized, double-blind, double-dummy, positive-controlled trial. Chin. There was no statistically significant difference in the incidence of adverse reactions during treatment of COVID-19 pneumonia between the LHQW group and the conventional drug group (RR = 0.51, 95% CI = 0.141.82, p = 0.297). Our meta-analysis was conducted in accordance with the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement (Moher et al., 2009), and registered with PROSPERO (CRD42020224180). Royal Botanic Gardens, Kew science (2021). The following information was collected from each qualifying study: first authors name, year, treating disease, sample size, number of male and female, age, adverse reactions, dispose or outcome of adverse reactions. In treating fine particulates PM2.5 (7.5mg/kg)-exposed model rats, LHQW significantly relieved the pathological changes of thickened alveolar septum, congestion of capillary, interstitial edema and infiltration of lymphocyte and neutrophil surrounding bronchiole [34]. Wang, Y., Greenhalgh, T., and Wardle, J. Front. Preliminary Study on the Inhibitory Effect of Lianhua Qingwen Capsule on virusMaster Degree. Lianhua Qingwen (LHQW) is a classical Chinese medical preparation, while one of its prescription compositions Maxingshigan Decoction has a history of more than thousand years to treat plague, and exhibits antiviral and lung protection actions [15,16]. Zhou X.P. Significant heterogeneity was detected for COVID-19 pneumonia (I2 = 76.0), hand-foot-mouth disease (I2 = 62.1), rheum (I2 = 88.2), and drowsiness of nervous system damage (I2 = 91.8). Chin. Vahl [Oleaceae; Forsythiae Fructus], Lonicera japonica Thunb. Effect of lianhuaqingwen capsules on airway inflammation in patients with acute exacerbation of chronic obstructive pulmonary disease. [Lamiaceae; 1-Menthol] (7.5g), Glycyrrhiza uralensis Fisch. The cochrane Collaboration's Tool for Assessing Risk of Bias in Randomised Trials. J. Pharmacovigilance. This review will elucidate the pre-clinical and clinical evidence of LHQW in lung protection and antiviral activities, and provide timely data delivery for the exploration of effective treatment strategies in the therapy of COVID-19. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Shi, M., Peng, B., Li, A., Li, Z., Song, P., Li, J., et al. The quantitative analysis of all eligible studies. The current meta-analysis was conducted to systematically evaluate the security of LHQW compared with conventional drug in clinical application. However, both groups did not differ in the rate of conversion to severe cases or viral assay findings. It may benefit the treatment of COVID-19 by the signaling pathways such as advanced glycation end products (AGE)-receptor of AGE (RAGE), TNF, sarcoma-associated herpesvirus infection, IL-17 and human cytomegalovirus infection [41]. Declaration of competing interest. Efficacy and Safety of Lianhua Qingwen Granule Combined with Oseltamivir in the Treatment of Influenza Virus Infection in Children. Pharmacol. For rheum, sample size could partially explain heterogeneity (p = 0.005), but not year of publication (p = 0.658) and treatment of the control group (p = 0.712). Lianhua Qingwen capsules have been proven to speed up symptoms recovery but no effect in preventing infections from worsening. Medicine (Baltimore). In this analysis, the incidence of adverse reactions during treatment of influenza was lower in the LHQW group compared to the conventional drug group (RR = 0.74, 95% CI = 0.630.87, p < 0.001). Since the adverse reactions of LHQW are relatively minor, these functional changes can be recovered. Literature analysis of Chinese patent medicine treatment in the observation period of Clinical Management of Corona Virus Disease 2019 (trial 6th edition). Data from our meta-analysis also failed to compare the security of LHQW with conventional drugs for treatment of COVID-19 pneumonia, which requires further investigation. Dr. Tan says that LianHua QingWen is not advisable for COVID patients who are experiencing a chilling sensation due to the infection. On March 27, 2019, Yiling Pharmaceutical Co. Ltd. amended the LHQW drug manual to include adverse reactions related to its clinical application. 12 (08), 140141. Case reports, unrelated studies, those with duplicate data, reviews, commentaries and animal-based studies were excluded from the current meta-analysis. (2010). China Central Television News (2020). doi:10.1111/jep.13614, Wang, Y. X., Zhang, K. Y., Huang, J. H., Han, S. L., Zhao, J. H., and Xu, Z. J. Recent advances have discovered that COVID-19 is a systematic disease targeting the lungs, vasculatures, and immune system, and involves severe lung inflammation and immune deficiency in terms of cytokine storm, neutrophil extracellular traps, as well as imbalance of lymphocyte subsets and so forth [[4], [5], [6]]. doi:10.1142/S0192415X20500378. These above ingredients are decocted, distilled, filtered, refrigerated, mixed well with powdered sugar, dextrin or starch, dried and finally made into LHQW (Chinese Pharmacopoeia, 2020). Avoid prolonged use. Received 2020 Jul 3; Revised 2020 Aug 9; Accepted 2020 Aug 16. The COVID-19 pneumonia epidemic has spread across the globe poses a significant challenge to public health worldwide. Lianhua Qingwen Capsules of Yiling Pharmaceutical Approved in mauritius. Efficacy of Lianhuaqingwen capsule compared with oseltamivir for influenza A virus infection: a meta-analysis of randomized, controlled trials. Adv. Since the outbreak of COVID-19, Lianhua Qingwen Capsules have been recommended by the official Chinese "Diagnosis and Treatment Protocol for COVID-19" and widely used in designated admission hospitals for COVID-19. These in vivo data further demonstrate the antiviral effects of LHQW as well as its lung protection role. Assoc. The LHQW group has a reduced incidence of gastrointestinal system damage than the conventional drug group (RR = 0.83, 95% CI = 0.740.93, p = 0.002). Furthermore, they identified two important metabolites, prostaglandin F2 and arachidonic acid, and their arachidonic acid metabolism pathway, as vital indicators of LHQW in treating influenza by using serum metabolomics analysis [19]. A total of 2,511 citations were identified, among which 1,796 irrelevant, animal studies or duplicate studies were excluded, for screen of titles and abstracts. Seven studies reported the adverse reactions of hepatobiliary system damage. Lianhua Qingwen(Forsythiae fructus 225 mg, Lonicerae japonicae flos 225 mg, Ephedrae herba (processed w/ honey) 85 mg, Armeniacae semen amarum (stir-baked) . Chakraborty C., Sharma A.R., Sharma G., Bhattacharya M., Lee S.S. SARS-CoV-2 causing pneumonia-associated respiratory disorder (COVID-19): diagnostic and proposed therapeutic options. Lianhua Qingwen Jiaonang with Chinese Characters; As per continuing post-marketing surveillance, there is still incessant sale and distribution even through social media platforms, such as Facebook, of Lianhua Qingwen Jiaonang with Chinese characters, which were verified as unregistered by the FDA. These results were different from our findings, which may be attributed to the limited number of adverse reactions reported in the previous study. It argued that there was thus no reasonable basis for the mass distribution of the medication to healthy individuals to begin with, let alone doing so in a way that took up transportation capacity and resources that were urgently needed elsewhere. Chinese Pharmacopoeia (2020). Clinical effectiveness and case analysis in 54 NCP patients treated with Lanhuaqingwen granules. Theoretical Study of the Anti-ncp Molecular Mechanism of Traditional Chinese Medicine Lianhua-Qingwen Formula (Lqf). doi:10.1136/bmj.327.7414.557, Hu, C., Liang, M., Gong, F., He, B., Zhao, D., and Zhang, G. (2020). LHQW is recommended by the National Health Commission of the Peoples Republic of China as a traditional Chinese medicine appropriate for COVID-19 pneumonia (trial version from Fourth to the Eighth Edition). Pract. Yiling Pharmaceutical (2021). Med. Accordingly, other biases were defined as low risk of bias. The risk of bias data is presented as a percentage, as shown in Figure 2. government site. ACE2, angiotensin-converting enzyme 2; ADRs, adverse drug reactions; AECOPD, acute exacerbation of chronic obstructive pulmonary disease; AGE, advanced glycation end products; ALI, acute lung injury; COPD, chronic obstructive pulmonary disease; COVID-19, Coronavirus Disease 19; EC50, median effective concentrations; HPLC, high performance liquid chromatography; IBV, influenza B virus; IFN, interferon; IL, interleukin; LHQW, Lianhua Qingwen; LPS, lipopolysaccharide; IP, interferon-inducible protein; MCP, monocyte chemoattractant protein; MIP, macrophage inflammatory protein; NF-B, nuclear factor-kappa B; RAGE, receptor of advanced glycation end products; SARS, Severe Acute Respiratory Syndrome; SARS-CoV-2, Severe Acute Respiratory Syndrome Coronavirus 2; TCM, traditional Chinese medicine; UPLC-DAD-QTOF-MS, ultraperformance liquid chromatography coupled with diode-array detector and quadrupole time-of-flight mass spectrometry, Coronavirus, SARS-CoV-2, Lianhua Qingwen, Antiviral activity, Complementary strategy, {"type":"clinical-trial","attrs":{"text":"NCT02867358","term_id":"NCT02867358"}}. Compared with oseltamivir, LHQW achieved a similar therapeutic effectiveness with reduction of the duration of illness and duration of influenza A virus H1N1 shedding [36]. Subgroup analysis showed the incidence of dizziness or headache was significantly reduced with LHQW group (RR = 0.54, 95% CI = 0.340.84, p = 0.006), no statistical difference was detected for drowsiness and legacy neuralgia. Fujian J. Progress on the efficacy and clinical application of Lianhua Qingwen capsule (LHQW). Traditional Chinese medicine treatment maintains homeostasis through interactions between the body and pathogens or establishing a balance between stimulating antiviral responses and suppressing overactive immune responses that leads to tissue damage (Shi et al., 2021). Common side effects are heart palpitations, nausea, and vomiting. Res. The incidence of nervous system damage was lower in the LHQW group compared to the conventional drug group (RR = 0.24, 95% CI = 0.180.32, p < 0.001). In addition, LHQW treatment efficiently impaired the nuclear export of the viral RNPl [24]. As a library, NLM provides access to scientific literature. 2015, 731765. doi:10.1155/2015/731765, Jin, L., Xu, Y., and Yuan, H. (2020). Statistical analysis was performed with Stata 14 software (Stata Corporation, College Station, TX, USA). 6 (26), 8485. Recent clinical evidence also showed that LHQW in combination with western medicines, such as the other antiviral drugs, is better than that not using LHQW during COVID-19 treatment, suggesting it would be beneficial as a supplementary strategy for treating COVID-19 [41,[44], [45], [46]]. Theoretical research basis and clinical efficacy of Lianhua Qingwen in treating Novel Coronavious pneumonica. It was found that the total effective rate of LHQW granules combined with abidor treatment (LHQW group) was significantly higher than that of abidor group (80.95 % vs 64.86 %), while the rate of severe illness was markedly lower (14.29 % vs 23.65 %) [44]. LHQW is now officially recorded in Chinese Pharmacopeia (2015 Edition) and has been used to treat viral influenza for more than one decade, including in the fight against SARS in 20022003 in China [17]. Combination of western medicine and Chinese traditional patent medicine in treating a family case of COVID-19. The results are expected to enhance its effectiveness against viruses. There was no statistically significant difference in the incidence of adverse reactions during treatment of herpes zoster between the LHQW group and the conventional drug group (RR = 0.80, 95% CI = 0.521.23, p = 0.302). 8600 Rockville Pike A recent meta-analysis came from Zhang and Liu, (2014), focused on treatment for influenza A (H1N1) with LHQW in conjunction with oseltamivir. No meta-regression was performed for COVID-19 pneumonia due to the limited number of studies. 12, 640782. doi:10.3389/fphar.2021.640782. Alternat Med. Compared with the conventional drug group, the incidence of disease recurrence was lower in the LHQW group, implied that LHQW might could regulate and enhance the immune function of the body. 43 studies on treatment of respiratory tract infection were examined, with 29 reporting adverse reactions. Business China. In our meta-analysis, information on adverse reactions was clearly reported in 12 of the 17 studies while the remaining five studies provided no specific evidence of adverse reaction specifically, and the incidence of adverse reactions was lower in LHQW group than that in the conventional drug group. There was no statistically significant difference in the incidence of adverse reactions during treatment of rheum between the LHQW group and the conventional drug group (RR = 0.46, 95% CI = 0.121.83, p = 0.270). Use Overdosage Contraindications Special Precautions Adverse Reactions Storage MIMS Class ATC . The control and improvement of the present COVID-19 situation in China could not be separated from the extensive participation of TCM, which has been proven effective by the clinical studies in COVID-19 patients [41,44,48,49]. Z., Wang, H. T., Han, X., Liu, C., Sun, Y. N., Liu, B., et al. Li L.C., Kan L.D. Retrospective clinical analysis on treatment of coronavirus disease 2019 with traditional Chinese medicine Lianhua Qingwen. There was no statistically significant difference in the incidence of heart rate and arrhythmia between the LHQW group and the conventional drug group (RR = 0.67, 95% CI = 0.231.93, p = 0.454). 6 (01), 6364. Clinical Drug Safety of Lianhuaqingwen Preparation: a Systematic Evaluation. LHQW capsules also showed a multi-access effects on anti-human influenza A virus H3N2, including the prevention effect on virus adsorption, inhibition on virus proliferation after adsorption and direct killing of the virus [25]. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. The authors report no declarations of interest. Effect of Maxing Shigan Tang on H1N1 influenza A virus-associated acute lung injury in mice. Related tags TCM COVID-19 China A two-week clinical trial led by renowned Chinese pulmonologist Zhong Nanshan has shown that consuming the botanical TCM product Lianhua Qingwen (LH) capsules and undergoing the standard . Med. Materia Med. Therefore, further attention should be paid to the occurrence of adverse reaction with LHQW among different age groups in the future. BMJ. Recently, Yu et al. Wu et al. 160, 105101. doi:10.1016/j.phrs.2020.105101, Xiao, M., Tian, J., Zhou, Y., Xu, X., Min, X., Lv, Y., et al. China Med. Jie Chen, Qin Chen and Hua-Qian Jin analyzed literatures. [Fabaceae; Glycyrrhizae Radix et Rhizoma] (85g) (Rivera et al., 2014; Royal Botanic Gardens, Kew, 2021; Royal Botanic Gardens, Kew science, 2021; The Plant List, 2021; Yiling Pharmaceutical, 2021). National Administration of Traditional Chinese Medicine: Traditional Chinese Medicine Is Involved in a Wide Range of Treatment and Early Intervention Has Good Effects. Ding Y., Zeng L., Li R., Chen Q., Zhou B., Chen Q., Cheng P.L., Yutao W., Zheng J., Yang Z., Zhang F. The Chinese prescription Lianhua Qingwen capsule exerts anti-influenza activity through the inhibition of viral propagation and impacts immune function.
How Many Years Did Jacob Work For Rachel, Ucla Baseball Coach Salary, When Did Magic Johnson Get Married, Articles L